Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Orum Therapeutics received U.S. FDA clearance for its IND application of ORM-1153, a novel CD123-GSPT1 degrader-antibody conjugate, enabling the company to initiate a Phase 1 study for treating relapsed or refractory acute myeloid leukemia and other hematologic malignancies by the end of 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You have a clear opening in targeted protein degradation therapies for blood cancers with FDA greenlight on Orum’s new drug. Early clinical trials will prove if you can outcompete in the precise antibody-conjugate cancer treatment market.

◆ Coverage

3 sources · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceclinical-trialhematologic-malignanciestargeted-therapycancer-treatment